Edward J. Ludwig Sells 12,000 Shares of Boston Scientific Co. (NYSE:BSX) Stock

Boston Scientific Co. (NYSE:BSX - Get Free Report) Director Edward J. Ludwig sold 12,000 shares of the company's stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $105.48, for a total transaction of $1,265,760.00. Following the completion of the transaction, the director now directly owns 24,398 shares of the company's stock, valued at approximately $2,573,501.04. The trade was a 32.97 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Boston Scientific Price Performance

BSX stock traded up $0.06 during trading on Friday, hitting $106.20. 3,966,417 shares of the stock traded hands, compared to its average volume of 6,179,673. Boston Scientific Co. has a one year low of $65.33 and a one year high of $107.17. The stock has a market cap of $156.51 billion, a price-to-earnings ratio of 84.96, a P/E/G ratio of 2.79 and a beta of 0.80. The company has a current ratio of 1.48, a quick ratio of 1.02 and a debt-to-equity ratio of 0.44. The company has a 50 day simple moving average of $96.44 and a 200 day simple moving average of $88.29.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 18.11%. Equities analysts expect that Boston Scientific Co. will post 2.83 EPS for the current fiscal year.

Hedge Funds Weigh In On Boston Scientific

Institutional investors and hedge funds have recently modified their holdings of the business. Parnassus Investments LLC grew its stake in Boston Scientific by 0.7% during the fourth quarter. Parnassus Investments LLC now owns 14,861 shares of the medical equipment provider's stock worth $1,327,000 after buying an additional 97 shares in the last quarter. Evergreen Capital Management LLC grew its stake in Boston Scientific by 1.7% during the fourth quarter. Evergreen Capital Management LLC now owns 6,331 shares of the medical equipment provider's stock worth $565,000 after buying an additional 106 shares in the last quarter. PDS Planning Inc grew its stake in Boston Scientific by 1.5% during the fourth quarter. PDS Planning Inc now owns 7,474 shares of the medical equipment provider's stock worth $668,000 after buying an additional 113 shares in the last quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA grew its stake in Boston Scientific by 9.7% during the third quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 1,352 shares of the medical equipment provider's stock worth $115,000 after buying an additional 119 shares in the last quarter. Finally, Adero Partners LLC grew its stake in Boston Scientific by 3.3% during the fourth quarter. Adero Partners LLC now owns 3,737 shares of the medical equipment provider's stock worth $334,000 after buying an additional 120 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

BSX has been the topic of a number of research reports. Barclays boosted their target price on shares of Boston Scientific from $111.00 to $118.00 and gave the stock an "overweight" rating in a report on Monday, February 10th. Deutsche Bank Aktiengesellschaft raised Boston Scientific from a "hold" rating to a "buy" rating and set a $108.00 target price for the company in a research report on Friday, January 10th. Bank of America upped their price target on Boston Scientific from $90.00 to $100.00 and gave the company a "buy" rating in a research report on Tuesday, October 22nd. Needham & Company LLC restated a "hold" rating on shares of Boston Scientific in a research report on Thursday, February 6th. Finally, Raymond James upped their price objective on shares of Boston Scientific from $119.00 to $122.00 and gave the company a "strong-buy" rating in a research note on Thursday, February 6th. One equities research analyst has rated the stock with a hold rating, twenty-two have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $107.39.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.